Delving into the Latest Updates on D-Serine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

D Serine

Target

NMDA receptor

Action

agonists

Mechanism

NMDA receptor agonists(Glutamate [NMDA] receptor agonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication-

Inactive Indication

Chronic schizophreniaParkinson DiseaseSchizoaffective disorder+ [2]

Originator Organization

Mass General Brigham, Inc.

Active Organization-

Inactive Organization

Nathan S. Kline Institute for Psychiatric Research

Bausch Health Cos., Inc.

Mass General Brigham, Inc.

+ [5]

License Organization

Prestwick Pharmaceuticals, Inc.Biovail Corp.

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC3H7NO3

InChIKeyMTCFGRXMJLQNBG-UWTATZPHSA-N

CAS Registry312-84-5

The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The investigators hypothesize that NMDA receptor activation via D-serine combined with repeated sessions of rTMS will produce greater clinical outcomes than iTBS with placebo and 18-Hz with placebo.

Start Date01 Apr 2025

Sponsor / Collaborator

McLean Hospital, Inc.

NCT04140773

/ TerminatedNot ApplicableIIT

The Effect of D-serine as add-on Therapy in Recent-onset Psychosis

In psychotic disorders, negative symptoms and cognitive impairment are difficult to treat with antipsychotics, which are mostly effective for positive symptoms. However, it is important that negative symptoms and cognitive impairment are treated as well, as they both play a large part in the acute episode and long-term course of schizophrenia outcome. Previous studies have used D-serine as add-on treatment in patients with psy-chotic disorders and high-risk patients, with positive results. So far, no study has investigated the effects in a sample of recent-onset psychosis patients.
Therefore, this study will include 30 patients (18-50 years old) with recent-onset psychosis. In addition to their regular treatment, patients will receive either D-serine (2 g/d) or placebo for 6 weeks. D-serine is an amino-acid naturally occurring in the brain which is prescription-free available as nutritional supplement.
The primary outcome measure is total score on the Positive and Negative Syndrome Scale (PANSS). Secondary measure-ments include PANSS subscales, neurocognitive tests, (f)MRI, and EEG

Start Date25 Nov 2021

Sponsor / Collaborator

University of Basel

NCT04721249

/ CompletedNot ApplicableIIT

A Randomized add-on Trial of D-serine for Depression

The glutamate system is emerging as target for the development of novel antidepressant medication, in particular compounds modulating the NMDA receptor. While the NMDA receptor antagonist ketamine is an effective option for many treatment-restistant patients, it is also accompanied by dissociative and cognitive effects and also bears the risk to develop addiction, side effects that are significantly restricting its clinical utility. There is now compelling evidence of the antidepressant potential of D-serine, a NMDAR co-agonist. Compared to ketamine, D-serine goes along without any psychotomimetic effects or other side effects and thus might be a prom-ising novel antidepressant.
This study represents the first randomized control trial to test the efficacy of D-serine as an adjuvant therapy in patients with depression and thereby adds to re-cent efforts to establish novel glutamatergic antidepressants. Besides clinical measures, this study also explores the biological mechanisms underlying D-serine's clinical effect.

Start Date01 Jul 2021

Sponsor / Collaborator

University of Basel

100 Clinical Results associated with D-Serine

Login to view more data

100 Translational Medicine associated with D-Serine

Login to view more data

100 Patents (Medical) associated with D-Serine

Login to view more data

3,532

Literatures (Medical) associated with D-Serine

01 Aug 2025·DYES AND PIGMENTS

A fluorescent probe for enantioselective recognition of amino acids in solutions, cells and zebrafishes

Author: Huang, Zong-Xing ; Ni, Chuan-Zhi ; Sun, Qi ; Zhu, Yuan-Yuan ; Gu, Shuang-Xi ; Fu, Shi-Wei ; Zhang, Fang-Qi ; Li, Yang

Binaphthyl-based chiral fluorescent probes (S)-/(R)-1 featuring a 2-methylthiophenimide unit were designed and synthesized.The fluorescent response to enantiomer pairs of amino acids revealed that (S)- and (R)-enantimer of the probe had chiral bias to L- and D-amino acids, resp.The compound (S)-1 showed outstanding enantioselective fluorescence enhancement toward 10 amino acids (Asn, Glu, Val, Leu, Met, Ser, Gln, Arg, Phe and Ala) in both solvents of EtOH/H2O and DMSO/H2O at the condition of pH 7.5.Extremely high enantiomeric fluorescence enhancement ratio (ef, [IL-I0]/[ID-I0]) were obtained for Asn (646.2), Glu (318.9), Val (255.6), Leu (252.4), Thr (223.9) in EtOH/H2O, and the ef values to Val, Ala, Ser, Glu, Arg, Gln were all larger than 20 in DMSO/H2O.Chiral fluorescent imaging of the four amino acids (Ser, Val, Arg and Gln) were obtained in both living cells and zebrafishes via the probe (R)-1, which provides a new concept for the diagnosis and treatment of diseases associated with amino acid racemization.Results of 1H NMR and HRMS revealed the enantioselective fluorescence enhancement mechanism.

01 Aug 2025·DYES AND PIGMENTS

Tetraphenylethylene based chiral AIEgen for enantioselective detection of chiral acids

Author: Wei, Keyue ; Feng, Hai-Tao ; Li, Qingyang ; Zhang, Wangyan ; Zhang, Xiuhua ; Chen, Miao-Miao ; Qi, Chunxuan ; Zhao, Weiwei

Enantioselective recognition is crucial in pharmaceutical anal. and life sciences but remains a significant challenge.Herein, we constructed two chiral probes named (1R, 2R)-CHDA-2TPE and (1S, 2S)-CHDA-2TPE, which exhibit typical aggregation-induced emission (AIE) properties.The chiral probes show high enantioselectivity to 11 kinds of chiral reagents.Notably, the fluorescence intensity ratio of the probe with L- and D-glutamic acid was up to 88.8.The ¹H NMR titration results suggested that the hydrogen bond is response for the recognition.These findings implied that the synthesized probes are promising candidates for analyzing chiral compounds

01 Jul 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Direct crystallization resolution of chiral compounds assisted by chiral ionic liquids through conformational matching

Author: Wang, Jingtao ; Wang, Mingyang ; Luo, Dawei ; Gong, Junbo ; Wang, Dongbo ; Sang, Jingting ; Zhang, Bowen ; Han, Dandan

Stereoselective recognition using "tailor-made" chiral ionic liquids (CILs) is an effective approach to obtaining enantiopure compounds through crystallization resolutionIn this study, CILs were used as additives to stereoselectively inhibit the nucleation and growth of unwanted enantiomers via a conformational matching mechanism.Interestingly, a cosolvency phenomenon was found in the threonine-CILs-ethanol solvent system.Based on this, an enhanced stereoselective crystallization resolution strategy that combines ultrasound and cosolvency was proposed.The goal of this strategy was to improve the crystallization yield and enantiomeric purity.The results showed that the crystallization resolution yield of the cosolvency system was 33.43%, higher than that of the pure water system (13.56%).More importantly, the introduction of ultrasonic enhancement further increased the crystallization resolution yield to 39.45%.This work will facilitate the exploration of the unlimited potential of utilizing the cosolvency phenomenon and ultrasonic enhancement for crystallization resolution

100 Deals associated with D-Serine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	D-Serine	-	DB03929

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Schizoaffective disorder	Phase 3	India	Yale University	01 Feb 2005
Schizophrenia	Phase 3	India	Yale University	01 Feb 2005
Chronic schizophrenia	Phase 2	Taiwan Province	China Medical University Hospital	01 Jan 2005
Parkinson Disease	Phase 2	-	Mass General Brigham, Inc.	-
Parkinson Disease	Phase 2	-	Bausch Health Cos., Inc.	-
Stress Disorders, Post-Traumatic	Phase 2	-	Bausch Health Cos., Inc.	-
Stress Disorders, Post-Traumatic	Phase 2	-	Mass General Brigham, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00817336 (CTgov)	Phase 2	Schizoaffective disorder \| Schizophrenia	16	D Serine (D-serine)	xreneehbde(ydxccetolu) = djcewpkaby mfablgfuhp (csusmemtbn, 9.3) View more	-	02 Aug 2017
				Placebo (Placebo)	xreneehbde(ydxccetolu) = knofubdpjg mfablgfuhp (csusmemtbn, 10.3) View more